Elsevier ob-gyn journal retracted paper after legal threat

When we broke the story last week about a juicy retraction notice in the American Journal of Obstetrics & Gynecology (AJOG) — known by its readers as “the Gray Journal” — we wrote that there was more to it than we suspected. That’s an understatement.

As we reported, the AJOG retracted an article that it had published earlier this year because 1) the author, Laurence Cole, had failed to disclose a potential financial conflict of interest with a pregnancy test maker named Church & Dwight; and 2) the article lacked a “credible scientific reason given for conducting the study,” along with other flaws detailed in the notice. (As we wrote the other day, we wonder why those issues did not arise during the initial review of the manuscript — but more on that shortly.)

We’ve since learned that the journal’s move came after it received a sharply worded letter from a high-powered San Francisco lawyer demanding immediate retraction of the article on the grounds that it represented a “substantial” threat to the financial health of his client. That client? A maker of home pregnancy tests who is now in the process of suing the very firm that provided Cole with research funding he failed to disclose.

First, here’s what Cole,  the hormone expert at the University of New Mexico whose paper the journal retracted, said about why he didn’t disclose that funding: Continue reading Elsevier ob-gyn journal retracted paper after legal threat

Ob-gyn journal pulls pregnancy test paper for undeclared conflict of interest, other problems

The American Journal of Obstetrics and Gynecology (AJOG) as a remarkable retraction notice in its November issue — the likes of which we haven’t seen before.

A little background: Earlier this year, Laurence Cole, an academic obstetrics specialist at the University of New Mexico in Albuquerque, published a paper in the AJOG looking at the wide variability in the hormone human chorionic gonadotropin, or hCG, during pregnancy (we’d link to the article, but the journal has pulled it, so here’s the abstract on Medline).

Cole runs — or did run until recently, more on that in a moment — the USA hCG Reference Service at the university, which purports to be the only lab in the world that can measure all forms of hCG. He has published extensively in this area of research, with at least 125 papers to his name on the subject, according to a Medline search. One of his websites puts the figure at 246.

So Cole was definitely a known quantity to the journal editors when he submitted his manuscript and when it was published online in February of this year. That’ll be more important in a bit. But first, the retraction notice: Continue reading Ob-gyn journal pulls pregnancy test paper for undeclared conflict of interest, other problems

Retracted retraction leaves Genomics paper intact — but authors wonder if anyone will know

Last March, the journal Genomics retracted a paper, “Discovery of transcriptional regulators and signaling pathways in the developing pituitary gland by bioinformatic and genomic approaches,” for reasons that don’t really fit into a tight lede sentence. Let’s just say that at times the problems involved both questions of authorship and the validity of the research. More on all that in a moment.

Meanwhile, things change. Now the journal, an Elsevier title, is un-retracting (that can’t be a real word, can it?) the retraction. You’d think that would please the authors, and it does to an extent. But they also wonder, legitimately, whether the original retraction will refuse to relinquish its grip on the resurrected article and consign it to database oblivion.

First, some background. Continue reading Retracted retraction leaves Genomics paper intact — but authors wonder if anyone will know

Another retraction for Naoki Mori (make that 23?)

The retraction total for Naoki Mori continues to rise.

The October issue of Biochemical and Biophysical Research Communications has retracted a 2007 paper by Mori et al for the same issues — manipulated images — that  brought down the 20-odd other papers of his since the scandal broke in late December.

Here’s the notice for the pulled paper, titled “Downregulation of citrin, a mitochondrial AGC, is associated with apoptosis of hepatocytes:” Continue reading Another retraction for Naoki Mori (make that 23?)

Mistaken notice as Ben Gurion researchers retract vitamin D paper for duplication

“Clare Francis,” a prolific pseudonymous Retraction Watch tipster, emailed us recently to flag a retraction in the Journal of Steroid Biochemistry and Molecular Biology (JSBMB) of “The anti-inflammatory activity of 1,25-dihydroxyvitamin D3 in macrophages,” a paper by Amos Douvdevani and colleagues at Ben Gurion University in Israel.

Here’s what we found when we clicked on the notice for the 2007 paper, which has been cited 32 times, according to Thomson Scientific’s Web of Knowledge:

This article has been retracted at the request of the authors, in response to concerns raised by the research committee at the authors’ institution. The authors stated the committee had given approval but the committee states no approval was given. The research committee has asked the authors to retract the paper and the authors have agreed.

That sounded odd to us, since it was unclear what approval was needed, or hadn’t been given. Continue reading Mistaken notice as Ben Gurion researchers retract vitamin D paper for duplication

*Savaskan and Nitsch, forced to retract FASEB J paper, correct Cell study with duplicated figure

In August, we wrote about the complicated case of a paper retracted from FASEB Journal that had originally been slated for a correction instead. There had been allegations of misconduct by one of the authors, Nicolai E. Savaskan, and the key parts of the retraction notice for the paper were as follows:

A well-recognized and top-class fact finding commission concluded that the publication contains gross flaws. A key figure (Figure 14) and the conclusions drawn from it could not be underlined with the corresponding primary data.

Savaskan told us at the time that FASEB Journal had agreed to a correction of the figure in question, but ended up retracting the paper after receiving a letter from Annette Gruters-Kieslich at Charite – Universitatsmedizin Berlin, where the work was done. We didn’t get much of an answer from FASEB Journal about why they changed their minds.

*Since understanding why one paper warrants a correction and another gets retracted is important for us at Retraction Watch, a correction of a 2009 Cell paper by a group that included Savaskan and his FASEB J c0-author Robert Nitsch caught our eye. The correction for “Synaptic PRG-1 Modulates Excitatory Transmission via Lipid Phosphate-Mediated Signaling” — a paper cited nine times so far, according to Thomson Scientific’s Web of Knowledge — ran in the September 16, 2011 issue of Cell: Continue reading *Savaskan and Nitsch, forced to retract FASEB J paper, correct Cell study with duplicated figure

The ‘Goldilocks’ retraction? Revealing differences in how several neurology journals handled related problems

Four neurology journals have retracted articles by a Japanese researcher who admitted to having made “mistakes” in his handling of data. Although the cases are related, the way the journals have handled the  notices is startlingly different. One chose to say nothing, one chose to say little, while two went for full — or at least, approximately that — disclosure.

Guess which ones we like the most? Continue reading The ‘Goldilocks’ retraction? Revealing differences in how several neurology journals handled related problems

Brown bear, brown bear, what do you see? I see fraud in sexual selection infanticide commentary

From the, No Further Explanation Required files:

The journal Animal Behaviour has retracted a 2009 article by an international group of researchers who, well, did just about everything one could do wrong with a paper.

Here’s the notice, res ipsa loquitur: Continue reading Brown bear, brown bear, what do you see? I see fraud in sexual selection infanticide commentary

Publisher error handling two eye papers leads to retractions, new policy on notices

We can only imagine how Joe Hollyfield felt to learn from us, of all people, that his journal, Experimental Eye Research, had retracted two manuscripts in a recent issue.

The papers, “Mechanisms of retinal ganglion cell injury and defense in glaucoma,” by Qu J, Wang D, and Grosskreutz CL, and “Mitochondria: Their role in ganglion cell death and survival in primary open angle glaucoma,” by Osborne, NN, carried the same retraction notices:

This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy.

Because in our experience such unhelpful wording often masks interesting details — read, author misconduct — we called Hollyfield for comment. He graciously walked us through the retractions, explaining the case in detail, until we realized that we were talking about different papers entirely. Hollyfield, it turned out, thought we were asking about the travails of Sangiliyandi Gurunathan, an eye researcher from India whom we’d previously covered and whose work recently had been retracted by Experimental Eye Research and other journals for image manipulation.

But Hollyfield was unaware of the two retractions we’d intended to talk about with him and told us he’d look into them.

Here’s what he learned: Continue reading Publisher error handling two eye papers leads to retractions, new policy on notices

New retractions of diabetes, cardiovascular papers from Japan involve repeat use of figures

At least four retractions have appeared involving the work of a group of Japanese researchers who appear to have reused figures — and doctored them — in multiple manuscripts.

The authors, led by Yoshiyuki Hattori, of Dokkyo University School of Medicine in Mibu (whose motto, by the way, is “where character is developed through learning” a reader points out that we had the wrong Dokkyo initially), published the same figure twice, and in the same year, in the Journal of Cardiovascular Pharmacology and Biochimica et Biophysica Acta.

Here’s a retraction notice from the JCP: Continue reading New retractions of diabetes, cardiovascular papers from Japan involve repeat use of figures